Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of quadrivalent HPV vaccine in Japanese men aged 16 to 26 years
2015-002931-16Phase 3
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of qHPV vaccine in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Incidence of HPV 6-, 11-, 16- or 18-related persistent infection and Combined incidence of HPV 6-, 11-, 16- or 18-related persistent infection detected in samples from two or more consecutive visits 6 months or longer apart.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2015-002931-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002931-16.